)
Visual
test
Sichuan Kelun-Biotech Biopharmaceutical
Sichuan Kelun-Biotech Biopharmaceutical (6990) investor relations material
Sichuan Kelun-Biotech Biopharmaceutical 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary15 Jan, 2026
Company overview and R&D focus
Specializes in novel drug development for oncology, immunology, metabolism, and other diseases, leveraging a differentiated OptiDC drug-conjugate platform.
Operates over 30 pipeline programs, with four approved products and two at NDA stage, and expects further approvals and label expansions in 2026.
Employs around 2,000 staff, with significant investment in R&D, manufacturing, and commercialization.
Product pipeline and clinical progress
Four products approved in China, including TROP2 ADC (sac-TMT) and HER2-ADC, with multiple indications in breast, lung, and GI cancers.
Nine novel drug conjugates in clinical stage, including bispecific and radioisotope ADCs, targeting major oncology indications.
Five pivotal clinical studies for breast cancer, six for lung cancer, and one for GI cancer underway; several Phase 1/2 programs expected to advance.
Clinical data from six pivotal studies and multiple early-phase studies presented at major conferences and published in top journals.
Commercialization and partnerships
Three core products included in China's National Reimbursement Drug List (NRDL 2025), effective this month.
Strategic collaborations with MSD, Ellipses, Windward Bio, and Crescent Biopharma to expand global reach and pipeline value.
MSD is a major shareholder and partner, with 16 global Phase 3 studies ongoing for sac-TMT in various cancers.
Commercial team established with access to major hospitals and key opinion leaders, with plans for further expansion.
Expected sales impact from NRDL 2025 inclusion
Earliest global Phase 3 data for SAC-TMT
OptiDC platform's competitive edge for new ADCs
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebSBIN
Q3 FY26 net profit reached ₹21,028.15 crore, driven by robust income and strategic divestments. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026. - 6 FebARI
Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy. - 6 FebSMCI
Q2 revenue jumped 123% to $12.7B, with FY26 guidance raised to at least $40B. - 6 FebRJF
Record revenues and assets, higher dividend, and acquisitions despite lower net income.
Next Sichuan Kelun-Biotech Biopharmaceutical earnings date
H2 202523 Mar, 2026
Sichuan Kelun-Biotech Biopharmaceutical
Next Sichuan Kelun-Biotech Biopharmaceutical earnings date
H2 202523 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a China-based company engaged in the research, development, and manufacturing of biopharmaceutical products. The company focuses on innovative therapeutics across various medical fields, including oncology, infectious diseases, and autoimmune disorders. It develops biologic drugs and biosimilars, utilizing advanced biotechnological platforms to address unmet medical needs. Sichuan Kelun-Biotech serves both domestic and international pharmaceutical markets. The company is headquartered in Chengdu, China, and its shares are listed on the Hong Kong Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage